http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110386918-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-06 |
| filingDate | 2018-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110386918-B |
| titleOfInvention | A kind of preparation method of 5-HT1F agonist compound |
| abstract | The present invention relates to a preparation method of a 5-HT1F agonist compound. The method utilizes 2,3-butanedione and 2-halogenated acrylonitrile through 1,4-addition reaction to obtain 2-halogenated-5,6-dioxo-n-heptanenitrile, and then cyclizes with ammonia through pyridine, Protect the amino group to obtain 2-disubstituted methylideneamino-6-acetylpyridine, and then prepare 2-disubstituted methylideneamino-6-(1-methylidene through hydroxyethylation reaction, sulfonic acid esterification reaction and methylamine condensation reaction 5-HT1F agonist compound Lasmiditan is obtained through deprotection reaction and 2,4,6-trifluorobenzoyl chloride amidation reaction. The method of the invention is easy to obtain raw materials, avoids ultra-low temperature reaction, simple and convenient to operate, low in cost, and easy to industrialize production of Lasmiditan. |
| priorityDate | 2018-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 144.